Lisa is a stock analyst with nearly 25 years of investment research experience. She earned a MBA in Finance from the University of Chicago in 1987 and began her career in investment research that same year as part of the equity research team at Kemper Financial Services. In 1989, Lisa joined the Financial Relations Board, a large investor relations consulting firm, rising to the position of director of financial analysis.
During her tenure with FRB, Lisa was a consultant to Boston Market, MGI Pharma, Devon Energy and other Fortune 1000 companies. In 2000, Lisa left to become director of investor Relations for a NYSE-listed REIT, serving in that position until the REIT was acquired. Since then, Lisa has worked as a stock analyst for independent research firms, investment newsletters and financial websites.
Analyst Articles
To many people, it’s hard to justify investing in companies that make such unloved products as tobacco, weapons or even alcohol. But income investors can find lots of reasons to like tobacco and alcohol stocks, namely their defensive nature and the fact that they typically perform quite well. Read More
It’s so important to learn from the nation’s top investors. You don’t need to tell that to the thousands that flock to Omaha, Nebraska once a year to glean fresh wisdom from Warren Buffett. Many others follow the actions of George Soros, Carl Icahn or others. These top investors have… Read More
My husband Melvin and I bought our first home when we were expecting our first child. After an exhaustive search, we settled on an up-and-down duplex. It was built in the 1940s and had a rental suite in the basement. The purchase was a good decision from… Read More
With all due respect to famed economist Burton Malkiel, but stocks don’t make a “random walk.” His famous book from 1973, A Random Walk Down Wall Street, opined that the stock market incorporates all information and there is… Read More
It might be the most controversial statement I’ve ever told investors… In fact, you’re likely to shrug me off at first, as what I’m about to tell you goes against everything you’ve been taught about wealth management. Read More
In this low interest rate environment, investors have turned to high-yielding blue-chips as a source of retirement income. This five-part series will outline what I believe to be the top five dividend aristocrat stocks, most suitable for a retiree’s portfolio. In my previous articles on… Read More
Low prices for this commodity are leading to new and innovative ways to use it. Read More
What on Earth is Steven A. Cohen thinking? He’s authorized traders at his investment firm, SAC Capital, to quickly build a large position in Accretive Health (NYSE: AH). Roughly a week ago, SAC announced that it had already bought so many shares that it… Read More
The second quarter of 2012 has been a bummer so far, especially when you think back to what was a great first quarter in which the S&P 500 rose more than 12%. But I’m not discouraged. While the recovery may be proceeding at an excruciatingly slow pace, I still think… Read More
To Europe’s leaders and Greek voters, here’s a modest request: Will you please flip over all the cards and make the bold moves that markets are increasingly expecting? At this point, providing further bailout funds for Greece is simply foolish. No amount of money can turn this… Read More
